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The signiﬁcance of occult metastases in axillary lymph nodes in patients with carcinoma of the breast is controversial.
Additional sections were cut from the axillary lymph nodes of 477 women with invasive carcinoma of the breast, in whom no
metastases were seen on initial assessment of haematoxylin and eosin stained sections of the nodes. One section was stained
with haematoxylin and eosin, and one using immunohistochemistry with two anti-epithelial antibodies (CAM5.2 and HMFG2).
Occult metastases were found in 60 patients (13%). The median follow-up was 18.9 years with 153 breast cancer related
deaths. There was no difference in survival between those with and those without occult metastases. Multivariate analysis,
however, showed that survival was related to tumour size and histological grade. This node-negative group was compared
with a second group of 202 patients who had one involved axillary node found on initial assessment of the haematoxylin and
eosin sections; survival was worse in the patients in whom a nodal metastasis was found at the time of surgery. Survival was
not related to the size of nodal metastases in the occult metastases and single node positive groups. Some previous studies
have found a worse prognosis associated with occult metastases on univariate analysis, but the evidence that it is an
independent prognostic factor on multivariate analysis is weak. We believe that the current evidence does not support the
routine use of serial sections or immunohistochemistry for the detection of occult metastases in the management of lymph
node negative patients, but that the traditional factors of histological grade and tumour size are useful.
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Axillary lymph node stage has traditionally been regarded as the
most powerful prognostic indicator in invasive carcinoma of the
breast. Furthermore, the greater the number of axillary node
metastases, the worse the prognosis. The fact that approximately
25% of patients without involvement of the axillary nodes subse-
quently developed distant metastases, however, has prompted the
search for other prognostic factors. One approach has been to
investigate the negative lymph nodes more thoroughly in an
attempt to ﬁnd metastases missed by conventional assessment.
Detection of nodal metastases depends on a number of factors
(Cserni, 2000). These include removal of sufﬁcient tissue from
the axilla of the patient (Reynolds et al, 1994), adequate dissection
of the specimen (Cserni, 1998), the method of sampling the nodes
for histological examination (Friedman et al, 1988), and the tech-
nique used to identify metastatic deposits within the histological
section. In the past, it was standard practice to sample only readily
palpable nodes and submit only half of each node for histology.
One haematoxylin and eosin (H&E) stained section of each node
was then examined microscopically. The value of axillary lymph
node stage as a prognostic factor was based on studies using this
methodology. Various methods for improving detection in surgical
specimens have been described, such as solvents to clear axillary
fat, X-ray of the specimen, or injecting radioisotope into the
patient prior to surgery and then scanning the patient and the
specimen. Little beneﬁt has been demonstrated using these techni-
ques, either in terms of yield of lymph nodes or, more importantly,
detection of involved nodes (Morrow et al, 1984). The majority of
lymph nodes can be relatively easily detected by careful palpation
of the specimen. One method of increasing the sensitivity of detec-
tion of metastases is to submit more of the lymph node for
histological examination, for example by cutting each lymph node
larger than 5 mm into slices, and submitting all the slices for histo-
logical examination.
Other methods of detecting metastases not seen with conven-
tional assessment include cutting additional sections, the use of
immunohistochemistry employing antibodies to epithelial markers,
and using polymerase chain reaction (PCR) to various RNA
sequences. Such deposits have been called occult metastases and
their signiﬁcance is uncertain. Most of the early studies found no
relationship between such metastases and prognosis. Some of the
more recent studies however have found an association between
occult metastases and less good prognosis. The current trend
towards sentinel node biopsy has highlighted the importance of
the method used to detect nodal metastases. There is now a consid-
erable debate as to how much effort should be put into examining
sentinel nodes before pronouncing them to be negative, and the
signiﬁcance of ﬁnding small metastases.
This study reports the prognostic signiﬁcance of occult metas-
tases detected using immunohistochemistry on axillary nodes
originally considered uninvolved in a large number of patients with
long follow-up, and compares them with patients with one
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size of axillary nodal metastases was also investigated.
MATERIALS AND METHODS
The patients were all treated in the Guy’s Hospital Breast Unit
between 1962 and 1981 for primary invasive carcinoma of the
breast. Two groups were studied. The ﬁrst group was composed
of 477 women, who at the time of surgery had no metastases seen
on histological assessment of H&E sections of the axillary lymph
nodes. One slice per node was examined. All patients underwent
modiﬁed radical mastectomy. Patients who were lost to follow-
up within a year were excluded. Three patients received adjuvant
tamoxifen, one had an ovarian ablation, and none received
chemotherapy. The median follow-up was 18.9 years (range 1.0–
34.8 years) in this group. There were 153 breast cancer related
deaths.
The second group was composed of 202 women, who had a
single involved node identiﬁed on histological assessment of H&E
sections of the axillary lymph nodes at the time of surgery. All
patients underwent modiﬁed radical mastectomy. Patients who
were lost to follow-up within a year were excluded. Eleven patients
received adjuvant tamoxifen, 11 received combined chemotherapy
(cyclophosphamide, methotrexate and 5-ﬂuorouracil) and 41
received melphalan. The median follow-up was 13.2 years (range
0.7–30.4 years) in this group. There were 111 breast cancer related
deaths.
The original histological sections of the surgical specimens of the
node negative patients were retrieved from the ﬁles. The primary
tumours were examined for histological type, histological grade
(Elston and Ellis, 1991) and the presence or absence of vascular
invasion. The blocks of the lymph nodes were recut at 3 mm.
One section was stained with H&E, and one using immunohisto-
chemistry with a combination of CAM5.2 (an antibody to
cytokeratins 8 and 18) and HMFG2 (an antibody to human milk
fat globulin). For the immunohistochemical stains the sections
were pre-digested with Trypsin. Non-speciﬁc staining was blocked
using calf serum. Antibody binding was demonstrated using a
streptavadin biotin technique. Positive and negative controls were
included with each batch of staining.
The aim of this study was to assess the signiﬁcance of occult
metastases detected on further H&E sections and immunohisto-
chemical sections. Thus we did not begin by assessing the initial
H&E sections. The recut H&E sections were examined ﬁrst and
if they showed a metastasis, then the original H&E sections were
reviewed. The immunohistochemical preparations were examined
next, and where a metastasis was identiﬁed, both the recut and
original H&E sections were reviewed. Occult metastases were cate-
gorised as ‘missed’ if they could be identiﬁed on the original H&E
sections, as ‘deﬁnite’ if they were seen on the recut H&E sections,
but not on the original H&E sections, and as ‘suspicious’ if they
were seen only on the immunohistochemical sections but could
not be identiﬁed on either of the H&E sections.
The size and site of all nodal deposits were noted in both the
node negative (with occult metastases) and single node positive
groups. Size was measured using an eyepiece graticule. Two
measurements were taken; one of the greatest diameter and the
other perpendicular to it, so that the involved area could be esti-
mated by multiplying the two diameters measured. Where there
was more than one deposit in a node, or more than one node
involved by occult metastases, the largest deposit was measured.
If multiple deposits within a node were separated by 1 mm or less,
they were considered as a single deposit and measured accordingly.
The site of a metastasis was deﬁned as parenchymal when within
the node substance with or without direct spread into the sinus,
capsule or through the capsule; sinusoidal when isolated deposits
occurred within the subcapsular sinus or a sinus within the node;
capsular or extracapsular when isolated deposits occurred within
these sites. If more than one site was involved, all sites were
recorded.
In the evaluation of overall survival only breast cancer related
deaths were considered. Survival curves were plotted using the
Kaplan–Meier method. The log rank test was used to compare
univariate survival curves, and Cox’s proportional hazards model
was used for the multivariate analysis.
RESULTS
Lymph node negative patients
A total of 6851 lymph nodes were examined from 477 patients
(median 14, range 1–41). Occult metastases were found in 60
patients. A single positive node was found in 55 patients, but in
three patients there were two, and in two patients there were three
involved nodes. The clinical and pathological features of patients
with and without occult metastases are shown in Table 1.
In 21 patients the occult metastases were detected on the recut
H&E section, of which eight could then be identiﬁed in the original
H&E section (‘missed’ metastases).
A further 39 patients had deposits detected on the immuno-
histochemical sections, of which 33 were then seen on the recut
H&E sections; in two patients these were also seen on the original
H&E sections (‘missed’ metastases). The metastases seen on the
recut H&E sections, but not on the original H&E sections, were
called ‘deﬁnite’ occult metastases.
In six patients, although positive cells were seen on the immu-
nohistochemical preparations, they could not be identiﬁed on the
H&E sections. Morphologically, however, the positive cells could
be diagnosed deﬁnitely as malignant. These were termed ‘sus-
picious’ occult metastases. These metastases were all very small,
in three cases consisting of only two or three cells, and in the other
three cases consisting of ﬁve to 10 cells. In another six cases posi-
tively stained cells seen only on the immunohistochemical sections,
could not be diagnosed as malignant on morphological grounds
and these patients were therefore not considered to have metas-
tases. Occult metastases were classiﬁed as missed in 10 patients,
deﬁnite in 44 and suspicious in six.
The median maximum diameter of the occult metastases was
0.37 mm (range 0.01–10 mm). The missed occult metastases
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Table 1 Clinical and pathological features of node negative patients with
and without occult metastases
Occult metastases
Percentage with
Absent Present occult metastases (%)
Tumour size (cm)
42 160 20 11
42–5 225 38 14
452 2 1 4
No size 10 1 –
Histology
Grade 1 ductal 60 8 9
Grade 2 ductal 138 20 13
Grade 3 ductal 147 15 9
Lobular 40 13 25
Tubular 18 2 10
Mucinous 12 0 0
Medullary 2 2 50
Vascular invasion
Present 76 14 16
Absent 341 46 12
Age median (range) 53 (33–77) 56 (23–81)
Total 417 60 13
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nite occult metastases (median 0.29 mm, 0.01–2.9 mm),
P50.0001, Mann–Whitney U), which in turn were larger than
the suspicious occult metastases (median 0.01 mm, 0.01–
0.03 mm), P=0.0003, Mann–Whitney U). Occult metastases were
parenchymal in 25, sinusoidal in 27, both parenchymal and sinu-
soidal in seven, and separate deposits were seen in the peripheral
sinus and the capsule in one node. All were present in nodes
low in the axilla.
Overall survival (Figure 1) and relapse free survival (w
2=1.8,
P=0.18) were not related to the presence of occult metastases,
nor was any difference found when metastases detected in different
ways (missed, deﬁnite, suspicious) were analyzed separately. Survi-
val in the originally node negative group was however signiﬁcantly
related to the following prognostic factors: tumour size
(P50.0001), histological grade (P=0.005) and the presence of
vascular invasion (P=0.01). On multivariate analysis, both tumour
size (P=0.0003, relative risk 1.19; 95% conﬁdence interval 1.08–
1.30) and histological grade (P=0.03, relative risk 1.29; 95% conﬁ-
dence interval 1.02–1.63) were independent predictors of survival,
whereas vascular invasion (P=0.07) and the presence of occult
metastases (P=0.30) were not. When the presence of occult metas-
tases was related to other pathological features, the only signiﬁcant
relationship was with tumour type. Patients with invasive lobular
carcinoma had occult metastases more frequently than patients
with invasive ductal carcinoma (25% vs 11%, w
2 with Yates correc-
tion=6.4, P=0.01). When patients with invasive lobular or invasive
ductal carcinoma were analyzed separately, the presence of occult
metastases still had no effect on survival (Lobular P=0.23, Ductal
P=0.35).
Patients with a single involved axillary node
The patients with a single positive node identiﬁed at the time of
surgery had a median of 22 nodes examined (range 1–52). As seen
in Figure 1 these patients had a worse survival than the node nega-
tive group. The difference in survival between patients with occult
metastases and a single node positive on original assessment was
also signiﬁcant (w
2=4.1, P=0.04). The size of the metastases in
the one-node positive patients was generally larger than that of
the occult metastases (median 5.0 mm, range 0.1–30 mm,
P50.0001, Mann–Whitney U).
Some of the patients from early in the study had only a small
number of lymph nodes examined, with a potential risk of under-
staging. Survival data were therefore reanalyzed, ﬁrstly including
only patients who had at least ﬁve, and then those who had at least
10 nodes examined. The results were essentially the same as in the
whole study group.
Survival was not related to either the area or the largest diameter
of the metastasis in the one-node positive and occult metastasis
patients (Figure 2), despite using different cut-offs. Similarly no
relationship was found between the site of the metastasis and survi-
val even after analyzing several different combinations to take into
account metastases involving more than one site.
DISCUSSION
There are two major unresolved questions regarding occult metas-
tases. Firstly, there is no agreed deﬁnition of an occult metastasis.
Secondly, the signiﬁcance of such metastases is uncertain.
Several different methods can be used to identify occult metas-
tases. Serial sections are time consuming, both for the technician
cutting the sections and for the pathologist examining the slides.
Immunohistochemistry for epithelial markers is much quicker to
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0         5         10       15       20       25       30        35      40
Time/years
At risk
417     352      285      249     187      54
 60       53        44       33       21        3
202     163      123      89      55        12
LN– occult met–
LN– occult met+
Single LN+
Figure 1 Overall survival of axillary node negative patients with and
without occult metastases, and of patients with a single involved axillary
node. There was no difference between node negative patients with and
without occult metastases w
2=1.9, P=0.17. Survival was worse in patients
with a single involved axillary node compared with the node negative group
w
2=32.7, P50.0001, and compared with the node negative patients with
occult metastases w
2=4.1, P=0.04. The table underneath shows patients
at risk at 5-yearly intervals.
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0         5         10       15       20       25       30        35      40
Time/years
At risk
Less than 0.2 mm
0.2 to 1.9 mm
2 to 9.9 mm
At least 10 mm
 23       19        16       11        9          2
 57       48       38       27       14        2
134     110      82       61       41        8
 48       39       31       23       12        3
Figure 2 Overall survival is not related to the size of the largest axillary
nodal metastasis in patients with occult metastasis or single node positive,
w
2=0.52, P=0.91. Metastasis size was divided using cut-offs of 0.2, 2 and
10 mm.
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patients whose axillary specimen is negative by conventional assess-
ment (Table 2). The ﬁgure of 13% for the present study is within
the reported range. Reverse transcriptase polymerase chain reaction
is even more sensitive, but it is difﬁcult to ﬁnd a RNA sequence
that is speciﬁc to tumours; it may be necessary to use a panel of
markers, particularly as the morphology of the positive cells cannot
be assessed (Liefers et al, 1999). With such high sensitivity there is
a risk of false-positive results.
There is no consensus on how nodal metastasis should be
measured, with considerable variation of methods between differ-
ent studies. A major problem is that two dimensional sections
are used to assess a three dimensional structure. Should the area
or greatest diameter be used? How should multiple metastases be
assessed? Further sections of nodes with multiple apparently sepa-
rate deposits might show whether they are joined or separate. Few
studies address these difﬁculties, and many give no details of meth-
odology. Some studies have classiﬁed nodal metastases according to
size, using the term micrometastases for small deposits, but the
cut-off has ranged between 0.2 and 2 mm. Although there is
evidence that larger axillary nodal metastases are associated with
a worse prognosis (Huvos et al, 1971; Fisher et al, 1978; Rosen
et al, 1981; Nasser et al, 1993; McGuckin et al, 1996; Cote et al,
1999), this is not so in all studies (Wilkinson et al, 1982; Hains-
worth et al, 1993) including the present one. Only two studies,
however, included multivariate analysis. One found that the size
of metastases was of prognostic signiﬁcance for relapse free survi-
val, but not for overall survival (McGuckin et al, 1996); the other
found that metastasis size was not an independent prognostic indi-
cator (Nasser et al, 1993). Subdivision of small nodal metastases
into ‘isolated tumour cells’ and ‘micrometastases’ has been
proposed (Hermanek et al, 1999). This may be useful for research,
but cannot be recommended for routine use. We are unable to
explain the discrepancy in the present study between the absence
of a relationship between metastasis size and survival and the fact
that patients with occult metastases (which tend to be smaller)
have a better survival than patients with a single positive node
on initial assessment.
The prognostic signiﬁcance of occult metastases is controversial.
Many of the early studies showed no relationship between occult
metastases and prognosis, but most had inadequate numbers of
deaths or recurrences for reliable evaluation of a prognostic factor
(Fayers and Machin, 1995). Some of the larger studies have shown
an association between occult metastases and a worse prognosis
(Table 2). This effect is more marked for disease free than for over-
all survival, but many studies used only univariate analysis. Only
one of the six larger studies found that occult metastases were an
independent predictor of poor prognosis, but only for relapse free
survival (Hainsworth et al, 1993). The largest studies, by the
Ludwig group (International (Ludwig) Breast Cancer Study Group,
1990; Neville et al, 1991; Cote et al, 1999), found that, on univari-
ate analysis, survival was worse for patients with occult metastases
detected with serial sections, but not for patients with occult
metastases identiﬁed with immunohistochemistry. Multivariate
survival analysis was not reported for occult metastases detected
with serial sections. There was worse survival associated with occult
metastases identiﬁed with immunohistochemistry in post-meno-
pausal women on multivariate analysis, but there was no such
analysis of the whole study group. One other group found an effect
in a different subgroup (Hainsworth et al, 1993).
Studies of the prognostic signiﬁcance of the position of metas-
tases within the node have produced conﬂicting results. Most,
including the present study, found no difference (Wilkinson et
al, 1982; Friedman et al, 1988; McGuckin et al, 1996), but a worse
prognosis was associated with parenchymal metastases in one study
(Nasser et al, 1993) and with sinusoidal metastases in another
(Hartveit and Lilleng, 1996). In one study all nodes with sinusoidal
metastases were found to have parenchymal metastases on deeper
sections (International (Ludwig) Breast Cancer Study Group,
1990). We examined deeper sections of several nodes with sinusoi-
dal metastases, but found parenchymal deposits only in a minority.
Immunohistochemistry detects more occult metastases than
additional H&E sections, particularly those consisting of small clus-
ters of cells or single cells. Single cells or clusters of a few cells seen
only on immunohistochemistry should only be accepted as metas-
tases if they are morphologically malignant. The nature of
cytokeratin positive cells without deﬁnite features of malignancy
is uncertain. Some may be malignant, but some could be the result
of benign epithelial transport (Carter et al, 2000). Dendritic cells
sometimes stain for cytokeratins, but their characteristic morphol-
ogy enables these cells to be recognized. Several studies, including
the present one, have shown that immunohistochemistry particu-
larly increases the likelihood of detection of metastases associated
with invasive lobular carcinoma (de Mascarel et al, 1992; McGuck-
in et al, 1996; Cote et al, 1999). Large metastases of lobular
carcinoma consisting of single malignant cells scattered widely
through a node can easily be missed on H&E sections. This
occurred in two cases in the present study. One study suggested
that immunohistochemically detected metastases were of prognos-
tic importance in invasive ductal but not in invasive lobular
carcinoma (de Mascarel et al, 1992), but the number of patients,
particularly with lobular carcinoma, was small. A larger study
found such metastases affected relapse-free survival of patients with
both tumour types, although no analysis of overall survival was
presented (Cote et al, 1999).
It is important that the relationship of survival and occult
metastases is not considered in isolation. Although lymph node
stage has traditionally been regarded as the most powerful prognos-
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Table 2 Studies of occult metastases and survival with at least 150 patients or at least 40 deaths or recurrences
No. of Deaths,
Method of
detection of occult % with occult
Prognostic signiﬁcance of occult metastases
Study patients recurrences metastases metastases Univariate Multivariate
Wilkinson et al (1982) 525 105, 139 Levels 17 No difference No analysis
I(L)BCSG (1990)
a 921 No details Serial sections 9 Worse RFS and OS No analysis
Neville et al (1991)
a 921 146, 287 Serial sections 9 Worse RFS and OS No analysis
Cote et al (1999)
a 736 189, 303 1 Serial sections 7 1 Worse RFS and OS 1 No analysis
2 Immuno 20 2 No signiﬁcant difference
b 2 No difference
b
Hainsworth et al (1993) 343 No details Immuno 12 Worse RFS, not OS
c No difference
c
Nasser et al (1993) 159 ?, 44 Levels and immuno 31 No difference
d Not for RFS
McGuckin et al (1996) 208 No details Levels and immuno 25 Worse OS and RFS Worse RFS, not OS
Colpaert et al (2001) 104 ?, 46 Immuno 23 No difference Better RFS
Present study 477 153, 178 Immuno 13 No difference No difference
Immuno=immunohistochemistry; OS=overall survival; RFS=relapse free survival; I(L)BCSG=International (Ludwig) Breast Cancer Study Group.
aSame series of patients;
bworse
prognosis in postmenopausal women;
cworse prognosis if at least two nodes with occult metastases;
dworse prognosis if occult metastases 40.2 mm.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 396–401tic indicator, recent evidence suggests that histological grade is of
at least comparable prognostic importance (Elston and Ellis,
1991; Galea et al, 1992; Sundquist et al, 1999). In unselected cases
tumour size is a less powerful prognostic factor, but nevertheless is
of independent value on multivariate analysis. In the present study
survival was associated with histological grade and primary tumour
size on multivariate analysis. Four of the studies in Table 2
reported univariate survival analysis for features of the primary
tumour: histological grade was signiﬁcant in all four (Wilkinson
et al, 1982; Hainsworth et al, 1993; McGuckin et al, 1996; Colpaert
et al, 2001), tumour size in three and vascular invasion in two.
Multivariate analysis was performed in four studies (Hainsworth
et al, 1993; Nasser et al, 1993; McGuckin et al, 1996; Colpaert et
al, 2001) with grade signiﬁcant in three and size in one.
In conclusion, this study found that occult metastases in axillary
lymph nodes, considered negative by conventional assessment, were
of no prognostic signiﬁcance. Although there are some studies
which have found a difference using univariate analysis, there is
little evidence that occult metastases are an independent predictor
of poor prognosis. By contrast, most studies have found that histo-
logical grade, and to a lesser extent tumour size, are of prognostic
value. We believe that the current evidence does not support the
routine use of either multiple sections or immunohistochemistry
for the detection of occult metastases in axillary clearance speci-
mens. There is some evidence that detection of occult metastases
in sentinel lymph nodes may be a useful predictor of metastases
in non-sentinel nodes and thus helpful in decisions about further
axillary surgery (Turner et al, 2000; Weaver et al, 2000; Kamath
et al, 2001). However, as with prognostic factors, features of the
primary tumour (such as size and vascular invasion) may also be
of value. The majority of studies of occult metastases in axillary
clearance specimens, including the present one, were from the
period when only one slice was taken from each lymph node for
histological examination. Recent guidelines from the UK breast
screening programme recommend more thorough sampling of axil-
lary lymph nodes (National Coordinating Group for Breast
Screening Pathology, 1995). We suggest that any future studies of
occult metastases should use large series of patients with long
and complete follow-up, with modern lymph node sampling tech-
niques, and that there should be multivariate analysis of survival
including traditional histological features particularly histological
grade and tumour size.
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